Veterinary Technologies Corporation (VetTech) is focused on the application of biotechnology in the development of vaccines, diagnostics and biowaste handling . Principals of the firm also offers consulting services and workshops in the areas of biotechnology, microbiology and immunology. For the product STANDARD RB51⢠- addressing Brucellosis in cattle - VetTech Has Marketing Agreements with: Schering-Plough which markets the vaccine throughout Central and South America as well as exclusive distribution rights for sub-Sahara Africa including South Africa. Hertape, S.A., has manufacturing rights in Brazil; with PRONABIVE of Mexico, a quasi-governmental private company, to produce and distribute in Mexico; with Indian Immunological Laboratories and Vet Tech have a joint venture to manufacture and sell the vaccine in India.; with CZV of Spain, to produce and market throughout Europe, the Middle East and Northwest Africa and Russia.; with United Biopharma of Egypt, to market in Northeast Africa including Egypt. The present brucellosis vaccine is manufacturered by Colorado Serum in Denver, Colorado. VetTech in conjunction with Colorado Serum Co. is working with Malaysia and Indonesia to market the vaccine in those countries and has opened a dialogue with China on introducing the vaccine there
